EdgeOne Venture Partners builds and operationalizes ventures where the therapy depends on the device — combination products, drug-device combinations, and cell & gene therapy delivery platforms. We are the venture affiliate of EdgeOne Medical, whose FDA-inspected, ISO 13485-certified labs serve 12 of the top 20 pharmaceutical companies.
Most venture models put capital in first and hope the operations follow. We work in the opposite order. Before any venture advances, it runs through months of hands-on device development, regulatory, and validation work in EdgeOne Medical’s labs. Technical risk, manufacturing risk, and team capability are proven through actual work — not presentations. We then stay at the table as the operational partner through development, clearance, and commercialization.
EdgeOne Venture Partners originates ventures from problems EdgeOne Medical sees repeatedly across its client base.
For venture builders, VCs, and family offices with device-dependent portfolio companies, we provide the operational scrutiny between biology validation and platform-scale device partnership — the diligence layer traditional venture processes miss.
Where operational validation proves out, we co-invest selectively alongside lead investors, and we co-create ventures with long-horizon capital partners. We do not lead rounds, and we are not currently deploying a fund into external opportunities.
We are currently developing two ventures, each addressing a distinct unmet need we have seen repeatedly across more than a decade of combination-product work. Consistent with our operating discipline, each advances through defined GO/NO-GO gates — on evidence, not on calendar. At the appropriate milestones, we will publish gate-review updates on these ventures in development.
Join our update list for gate-review updates on ventures in development.
Questions in the meantime? Write to info@edgeonemedical.com.
